October 17, 2018 06:49 AM EDTUpdated 11:22 AM
R&D

Roche torch­es a moun­tain of biobucks, sweep­ing out a ros­ter of drugs in the lat­est pipeline cleanup

John Carroll

Editor & Founder

While Roche $RHH­BY post­ed its Q3 up­date on the num­bers, high­light­ing the im­por­tance of its new block­busters in re­plac­ing some ag­ing fran­chis­es, the R&D group …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Aca­dia snaps up an es­sen­tial tremor drug af­ter field­'s sum­mer set­backs

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

A service from the Financial Times